Invesco Dynamic Pharmaceuticals ETF

PJP tracks an index of US pharmaceutical companies selected and weighted based on various factors using a quantitative methodology.

Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?

Virtus LifeSci Biotech Clinical Trials ETF

VanEck Vectors Biotech ETF

First Trust NYSE Arca Biotechnology Index Fund

iShares Nasdaq Biotechnology ETF

iShares U.S. Pharmaceuticals ETF

iShares U.S. Healthcare Providers ETF

iShares U.S. Medical Devices ETF

iShares U.S. Healthcare ETF

Invesco Dynamic Biotechnology & Genome ETF

VanEck Vectors Pharmaceutical ETF

Invesco S&P 500 Equal Weight Health Care ETF

Vanguard Health Care ETF

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

SPDR S&P Pharmaceuticals ETF

How SVB's collapse is impacting healthcare startups. Pfizer to buy Seagen for $43B.

The Fall Of SVB: What It Means For Healthcare Startups

Nasdaq Pharm Shs Nasdaq Pharmaceuticals

Combining the actual results with the estimates for the still-to-report companies, total earnings for the healthcare sector are expected to decline 9% on revenue growth of 4.3%.

A Look at Pharma ETFs Post Q4 Earnings

Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Global X Longevity Thematic ETF 

ARK Genomic Revolution Multi-Sector ETF

Virtus LifeSci Biotech Products ETF

BlackRock Future Health ETF

Principal Healthcare Innovators Index ETF

Loncar Cancer Immunotherapy ETF

Global X Telemedicine & Digital Health ETF

Fidelity MSCI Health Care ETF

First Trust Health Care AlphaDEX Fund

ETFMG Treatments Testing & Advancements ETF

Global X Genomics & Biotechnology ETF

 Franklin Genomic Advancements ETF

ROBO Global Healthcare Technology and Innovation ETF

Invesco Nasdaq Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

iShares Global Healthcare ETF

Eli Lilly

Global X Longevity Thematic ETF

First Trust Indxx Medical Devices ETF

Merck

Novo Nordisk

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Simplify Health Care ETF

Invesco S&P SmallCap Health Care ETF

Invesco DWA Healthcare Momentum ETF

ALPS Medical Breakthroughs ETF

Wisdomtree BioRevolution Fund

SPDR S&P Health Care Equipment ETF

SPDR S&P Health Care Services ETF

How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.

Can Health Care Stocks Outperform Again In 2023?

Subversive Decarbonization ETF

Subversive Food Security ETF

Subversive Mental Health ETF

The debut highlights the lack of funds focused on the area.

Subversive Launches ETF to Focus on Mental Health

Amgen

Horizon Pharma

Amgen (AMGN) has agreed to buy Horizon Therapeutics PLC (HZNP) for $27.8 billion. This put the spotlight on pharma ETFs, which could be the best way for investors to tap the opportunity arising from the proposed deal.

Amgen to Buy Horizon Therapeutics: ETFs to Bet On

The Q3 earnings picture for the healthcare sector seems solid, with results from companies that have reported so far up 2.1% on 5.8% revenue growth.

Pharma ETFs in Focus Post Q3 Earnings

Investors looking for equities suddenly have more than a few options to consider in this mini-market rally. Whether markets have really priced in Fed action or a possible recession already or not, investors should take a look at healthcare ETFs offering consistency in a strong year for health insurers and pharmaceutical firms.

3 ETFs for the Healthcare Sector's Highs

The recently enacted Inflation Reduction Act looks to rein in prescription drug prices and could impact the pharma industry's long-term financial performance. The legislation caps out-of-pocket costs for Medicare prescriptions at $2,000 per year, starting in 2025.

What The Inflation Reduction Act Means For Drug Prices

iShares Evolved U.S. Innovative Healthcare ETF

Pharma and biotech ETFs are in great shape and are trading at a one-month high level.

Pharma & Biotech ETFs at One-Month High: Here's Why

Many industry bigwigs reported solid results with some beating on earnings or revenues or both.

Pharma ETFs in Focus Post Q1 Earnings

GlaxoSmithKline

Johnson & Johnson

Sanofi

The pending separation of consumer care businesses by pharmaceutical companies is understandable and may offer investment opportunities.

Pharma In Transition: Context And Opportunities

Solid earnings failed to impress pharma ETFs over the past month due to a broad sell-off in the market.

Solid Q4 Earnings Fail to Impress Pharma ETFs

Pharmaceuticals companies, even the old, large-cap variety, are innovators in their own right. They have to be.

Big Pharma Innovation Outlook Looks Healthy

The S&P 500 Health Care Index is up 18% year-to-date, an admiral though not spectacular performance. While coronavirus vaccines remain a point of much discussion, pharmaceuticals stocks also fit the bill as solid though not spectacular.

Economics, Patents Critical for Pharmaceuticals Innovation, Equity Prices

The slew of Q3 results has led to smooth trading in pharma ETFs over the past month.

Wave of Solid Q3 Earnings Push Pharma ETFs Higher

The Invesco Dynamic Pharmaceuticals ETF (NYSEArca: PJP) is off 3.66% month-to-date, and the source of that lethargy is easy to spot: The drug price reform debate is once again gaining momentum, prompting investors to take a cautious approach to pharmaceuticals stocks. While the healthcare sector and pharmaceuticals stocks in particular have histories of being sensitive [.

Blue-Chip Pharmaceuticals Stocks Contend With Political Headwinds

The healthcare sector is getting its groove back, as a variety of exchange traded funds dedicated to the group are printing or residing near new highs. The Invesco Dynamic Pharmaceuticals ETF (NYSEArca: PJP) is part of that group and closed just 2% below its all-time high last Friday.

Looking for Healthier Healthcare Stocks?

Pharma ETFs Gain on Q2 Earnings

Upbeat earnings, COVID-19-related sales, compelling valuation and lucrative dividend prospects are boosting pharma and healthcare ETFs.

Pharma & Healthcare ETFs at a One-Year High: Here's Why

Direxion Daily Healthcare Bull 3x Shares

Tekla Healthcare Investors

Tekla Life Sciences Investors

Defiance Nasdaq Junior Biotechnology ETF

John Hancock Multifactor Healthcare ETF

Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

ProShares UltraShort Health Care

ProShares Ultra Health Care

Tekla Healthcare Opportunities

Pacer BioThreat ETF

The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively resilient throughout the pandemic, we expect a full recovery in the latter half of this year, as operations that were disrupted return to normal.

Biotech Innovations Remain At Forefront

Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12, 36% of the entire US population has received at least one vaccine, and 79% of those aged 65 years and older.

Moving Beyond COVID In Biopharma

AbbVie

LeMaitre Vascular

The advantage for dividend investors in this sector is the wide choice of large and well-established companies. AbbVie is a drug company with strong exposure to the immunology and the oncology markets.

Healthcare: A Wide Choice Of Large And Well-Established Companies

Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.

Pharma ETFs in Focus Post Q4 Earnings

News for Invesco Dynamic Pharmaceuticals ETF ETF (PJP)